Live Market Intelligence
Signal
Where precision medicine is heading, read four ways: market performance, scholarly diffusion and adoption, the gap between scientific push and clinical pull, and the live clinical-trial pipeline.
Start here
The Signal in Five Charts
The whole argument in one guided read — market eras, where each technology sits, scientific push vs. clinical pull, the research-to-clinic shift, and how the literature leads the market.
The Market
The Pulse
View scorecard →Precision Medicine Scorecard
Equal-weighted baskets tracking tools, diagnostics, and genomics companies across six market eras — from NicheOmics to ClinOmics. Indexed to Jan 2019.
NicheOmics
Under the radar
SwabRush
Diagnostics to the rescue
GenomicWinter
The reckoning
LiquidLift
Liquid biopsy leads
MarginOmics
Specialty Dx catches up
ClinOmics →
Clinical pull drives tool spend
The Diffusion Index
Where each precision-medicine technology sits in its diffusion lifecycle — read from ~200,000 publications — and what that says about the move into the clinic.
The Adoption Index
Eight technologies on the Rogers curve
Every technology, every year, placed on the adoption curve — the synthesis view across all the curves.
Explore →Push vs. Pull
Where science is racing ahead of the clinic
Scientific momentum vs. clinical pull. cfDNA broke through; NGS is infrastructure; the rest sit in the translation gap.
Explore →Anatomy of Diffusion
Where the papers go
The research-to-clinic migration by application, plus open-access and journal-discipline trends across all eight.
Explore →Cross-technology views: NGS Diffusion Atlas · All indexes side by side · Year-zero overlay
By technology
NGS
Peaked 2008, commodity by 2016 — the completed precedent
Single-cell RNA-seq
Chasm crossed; the floor is now in sight
Spatial transcriptomics
Following NGS 12 years later — compressing faster
Spatial proteomics
The protein complement to spatial Tx
Long-read sequencing
Adopted as infrastructure, not a paradigm shift
cfDNA & liquid biopsy
The clinical outlier — flat on the top-3 scale
Multi-omics
A pioneer term gone generic — still exploding
High-plex multi-omics
The real signal the broad term hid — still rising
The Clinical Pipeline — live evidence
Clinical Pull Index
Assays in Active Trials
Signatera recruiting trials — leading the field
Which precision Dx assays are named in active clinical trials worldwide. The most direct measure of clinical pull.
Explore →MRD Expansion Tracker
MRD Moves Into Solid Tumors
recruiting MRD trial records across tracked cancers (searches overlap)
MRD began in leukemia and myeloma. It's now expanding into lung, colorectal, and breast cancer via ctDNA — the frontier opportunity.
Explore →ctDNA SoC Countdown
Phase 3 Trials Using ctDNA to Decide Treatment
Phase 3 trials recruiting now
Each Phase 3 trial testing ctDNA-guided treatment is one readout away from a new standard of care — and a commercial platform requirement.
Explore →MCED Watch
The Population-Scale Bet
planned participants in major MCED trials
One of the largest clinical investments in oncology history. Zero routine reimbursements. NHS and PATHFINDER 2 read out in 2026.
Explore →Market data refreshes hourly. Clinical trial counts refresh daily from ClinicalTrials.gov. Counts reflect publicly registered studies and may undercount real-world usage. See the full methodology & limitations for data sources, definitions, the AI-classification process, and known caveats.